QT(c)-interval prolongation associated with slow intravenous erythromycin lactobionate infusions in critically ill patients: A prospective evaluation and review of the literature

Pharmacotherapy

Volumn 16, Issue 4, 1996, Pages 663-674

  Tschida, Suzanne J ^a,b   Guay, David R P ^a,b   Straka, Robert J ^a,b   Hoey, Lori L ^a,b   Johanning, Rebecca ^a,b   Vance Bryan, Kyle ^a,b,c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b REGIONS HOSPITAL   (United States)

^c ValueRx   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; ERYTHROMYCIN; SULTAMICILLIN; ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CRITICAL ILLNESS; ELECTROCARDIOGRAM; FEMALE; HUMAN; INTENSIVE CARE; INTRAVENOUS DRUG ADMINISTRATION; LONG QT SYNDROME; MALE; PNEUMONIA; SEPSIS; SUDDEN DEATH; TORSADE DES POINTES; CHEMICALLY INDUCED DISORDER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ELECTROCARDIOGRAPHY; MIDDLE AGED; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CRITICAL ILLNESS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; ERYTHROMYCIN; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LONG QT SYNDROME; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 0029661890     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. c effect. Am J Cardiol 1993;72:4B-9.
2. c prolongation on the electrocardiogram to torsades de pointes: definitions and mechanisms. Am J Cardiol 1993;72:10B-13.
3. McComb JM, Campbell JP, Cleland J. Recurrent ventricular tachycardia associated with QT prolongation after mitral valve replacement and its association with intravenous administration of erythromycin. Am J Cardiol 1984;54:922-3.
4. Gueugniaud PY, Guerin C, Mahul P, Deu C, Robert D. Torsades de pointes induits par l'association lidocaïne-érythromycine et insuffisance hépatique. Presse Med 1985;14:896.
5. Guelon D, Bedock B, Chartier C, Haberer JP. QT prolongation and recurrent "torsades de pointes" during erythromycin lactobionate infusion. Am J Cardiol 1986;58:666.
6. Freedman RA, Anderson KP, Green LS, Mason JW. Effect of erythromycin on ventricular arrhythmias and ventricular repolarization in idiopathic long QT syndrome. Am J Cardiol 1987;59:168-9.
7. Hummel JC, Haberer JP. Arrêt circulatoire peropératoire après injection intraveineuse de lactobionate d'érythromycine. Ann Fr Anesth Reanim 1988;7:85-6.
8. Kilani F, Marsepoil T. Accès de torsades de pointes induits par une injection intraveineuse de lactobionate d'érythromycine. Ann Fr Anesth Reanim 1988;7:270-1.
9. Lindsay J, Smith MA, Light JA. Torsades de pointes associated with antimicrobial therapy for pneumonia. Chest 1990;98:222-3.
10. Nattel S, Ranger S, Talajic M, Lemery R, Roy D. Erythromycin-induced long QT syndrome: concordance with quinidine and underlying cellular electrophysiologic mechanism. Am J Med 1990;89:235-8.
11. Schoenenberger RA, Haefeli WE, Weiss P, Ritz RF. Association of intravenous erythromycin and potentially fatal ventricular tachycardia with QT prolongation (torsades de pointes). BMJ 1990;300:1375-6.
12. Benoit A, Bobiou C, Villain E, Bavoux F, Checoury A, Badoual J. QT long et arrêt circulatoire après une injection d'érythromycine chez un nouveau-né. Arch Fr Pediatr 1991;48:39-41.
13. Oberg KC, Bauman JL. Incidence of QT prolongation and torsades de pointes due to erythromycin lactobionate [abstr]. Pharmacotherapy 1993;13:674A1.
14. Farrar HC, Walsh-Sukys MC, Kyllonen K, Blumer JL. Cardiac toxicity associated with intravenous erythromycin lactobionate: two case reports and a review of the literature. Pediatr Infect Dis J 1993;12:688-91.
15. Gitler B, Berger LS, Buffa SD. Torsades de pointes induced by erythromycin. Chest 1994;105:368-72.
16. Rezkalla, MA, Pochop C. Erythromycin induced torsades de pointes: case report and review of the literature. S D J Med 1994;47:161-4.
17. de Koning J, van der Hoeven, Hamer B, Thompson J. Erythromycin-induced torsades de pointes and ventricular fibrillation in a patient with Legionella pneumonia. Neth J Med 1994;44:131-5.
18. Brandriss MW, Richardson WS, Barold SS. Erythromycin-induced QT prolongation and polymorphic ventricular tachycardia (torsades de pointes): case report and review. Clin Infect Dis 1994;18:995-8.
19. Haefeli WE, Schoenenberger RA, Weiss PH, Ritz R. Possible risk for cardiac arrhythmia related to intravenous erythromycin. Intensive Care Med 1992;18:469-73.
20. Skaikowsky F, Haziza F, Guidet B, Vassal T, Offenstadt G. Accès de torsades de pointes au cours d'une maladie legionnaires: une accident exceptionel de l'érythromycine. Rev Pneumol Clin 1991;47:92-4.
21. Ragosta M, Weihl AC, Rosenfeld LE. Potentially fatal interaction between erythromycin and disopyramide. Am J Med 1989;86:465-6.
22. Orban Z, MacDonald LL, Peters MA, Guslits B. Erythromycin-induced cardiac toxicity. Am J Cardiol 1995;75:859-61.
23. Jackman WM, Friday KJ, Anderson JL, Aliot EM, Clark M, Lazzara R. The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. Prog Cardiovasc Dis 1988;31:115-72.
24. Makker RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993;270:2590-7.
25. Tan HL, Hou CJY, Lauer MR, Sung RJ. Electrophysiologic mechanisms of the long QT interval syndromes and torsades de pointes. Ann Intern Med 1995;122:701-14.
26. Stratman HG, Kennedy HL. Torsades de pointes associated with drugs and toxins: recognition and management. Am Heart J 1987;113:1470-82.
27. Bazett HC. An analysis of the time-relations of electrocardiograms. Heart 1918;7:353-70.
28. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
29. Ponsonnaille J, Citron B, Richard A, et al. Etude électrophysiologique des effects pro-arythmogènes de l'érythromycine. Arch Mal Coeur 1988;81:1001-8.
30. Rubart M, Pressler M, Pride HP, Zipes DP. Electophysiological mechanisms in a canine model of erythromycin-associated long QT syndrome. Circulation 1993;88:1832-44.
31. Houin G, Tillement JP, Lhoste F, Rapin M, Soussy CJ, Duval J. Erythromycin pharmacokinetics in man. J Int Med Res 1980;8(suppl 2):9-14.
32. Parsons RL, David JA, Raymond K, Stamp SM. Pharmacokinetics of intravenous erythromycin lactobionate. J Int Med Res 1980;8(suppl 2):15-23.
33. Nilsen OG. Comparative pharmacokinetics of macrolides. J Antimicrob Chemother 1987;20(suppl B):81-8.
34. 14C]-erythromycin in the guinea pig. Arzneimittelforschung 1987;37:524-7.
35. Mees N, Southard JH, Belzer FO. Inhibition of ischemic induced cellular swelling in kidney cortex tissue by lactobionate anions. J Trauma 1982;22:118-120.
36. Wilt JL, Minnema AM, Johnson RF, Rosenblum AM. Torsade de pointes associated with the use of intravenous haloperidol. Ann Intern Med 1993;119:391-4.
37. Hulisz DT, Dasa SL, Black LD, Heiselman DE. Complete heart block and torsade de pointes associated with thioridazine poisoning. Pharmacotherapy 1994;14:239-45.
38. Wharton JM, Demopulos PA, Goldschalger N. Torsade de pointes during administration of pentamidine isethionate. Am J Med 1987;83:571-6.
39. Janssen Pharmaceutica. Propulsid (cisapride) package insert. Titusville, NJ; 1995.
40. Moss AJ, Schwartz PJ, Crampton RS, Locati E, Carleen E. The long QT syndrome: a prospective international study. Circulation 1985;71:17-21.
41. c interval prolongation: a review. Am J Cardiol 1993;72:23B-5.
42. Moss AJ, Robinson J. Clinical features of the idiopathic long QT syndrome. Circulation 1992;85(suppl 1):I-140-4.
43. Morganroth J, Brozovich FV, McDonald JT, Jacobs RA. Variability of the QT measurement in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia. Am J Cardiol 1991;67:774-5.
44. Funck-Bretano C, Jaillon P. Rate-corrected QT interval: techniques and limitations. Am J Cardiol 1993;72:17B-22.
45. c prolongation measured by standard 12-lead electrography is an independent risk factor for sudden death due to cardiac arrest. Circulation 1991;83:1888-94.
46. Siepman N, Blahunka KS, Harris SI, Palmer RN. ECG changes observed following multiple dose co-administration of clarithromycin (C) and terfenadine (T) [abstr]. Pharmacol Res 1993;10:S354.
47. c interval. Am J Cardiol 1993;72:53B-4.
48. McEvoy GK, Litvak K, Welsh OH, Eds. AHFS 96 drug information. Bethesda, MD: American Society of Health-Syst Pharmacists, 1996:1198.
49. Grayson HA, Kennedy JD. Torsades de pointes and nifedipine. Ann Intern Med 1982;97:144.
50. Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 1992;52:231-8.
51. Price Evans DL. Genetic factors in drug therapy: clinical and molecular pharmacogenetics. Cambridge: Cambridge University Press, 1993.
52. Slaughter RL, Edwards DJ. Recent advances: the cytochrome P450 enzymes. Ann Pharmacother 1995;29:619-24.